Loading...
Market
What will be UroGen Pharma's cash reserves by end of Q1 2025?
3
Resolution / Starting Odds
Less than $200 million • 25%
$200 million to $250 million • 25%
$250 million to $300 million • 25%
More than $300 million • 25%
UroGen Pharma financial reports
Story
UroGen Pharma Completes NDA Submission for UGN-102, Awaits FDA Decision by Q1 2025
Aug 14, 2024, 11:40 AM
UroGen Pharma has successfully completed the submission of its New Drug Application (NDA) for UGN-102, an investigational drug aimed at treating low-grade intermediate-risk non-muscle invasive bladder cancer. The company is ahead of schedule in this process and anticipates a potential FDA decision as early as the first quarter of 2025, assuming priority review. UroGen reported its 2024 second-quarter financial results, highlighting $241.3 million in cash and net product revenues of $21.8 million from JELMYTO®.
View original story
Similar markets
Above $200 million • 25%
Between $100 million and $200 million • 25%
Between $50 million and $100 million • 25%
Below $50 million • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $150 million • 25%
More than $150 million • 25%
Below $3 billion • 25%
$3 billion to $5 billion • 25%
$5 billion to $7 billion • 25%
Above $7 billion • 25%
Below $30 billion • 25%
$30 billion - $33 billion • 25%
$33.01 billion - $36 billion • 25%
Above $36 billion • 25%
Less than $25 million • 25%
$25 million to $50 million • 25%
$50 million to $75 million • 25%
More than $75 million • 25%
Profitable • 25%
Break-even • 25%
Loss-making but stable • 25%
Facing financial distress • 25%
Less than $400 million • 25%
$400 million to $475 million • 25%
$475 million to $550 million • 25%
More than $550 million • 25%
Under $1 billion • 25%
$1 billion to $5 billion • 25%
$5 billion to $10 billion • 25%
Over $10 billion • 25%
Less than $1 billion • 25%
$1 billion - $1.5 billion • 25%
$1.5 billion - $2 billion • 25%
More than $2 billion • 25%